Double-edged news

Pfizer's vaccine is not necessarily great news for India

Topics
Coronavirus Vaccine | Pfizer

Business Standard Editorial Comment  |  New Delhi 

In news that is calculated to buoy markets globally, a major pharmaceutical manufacturer has said that its Covid-19 vaccine candidate has 90 per cent efficacy and has shown no major side effects in Phase-III trials. This is the BNT162b2 vaccine from Pfizer, which was being developed by the small German company BioNTech.

So far, little is known beyond the press release from the pharma major, and most experts have cautioned against prejudging the detailed medical data to follow. And, of course, the final decision will be taken by regulators, first in Europe, then in the United States, and ...

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 09 2020. 23:38 IST
RECOMMENDED FOR YOU
.